Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7617789

Cost-effectiveness analysis.

T G Ganiats
View original source ↗Export metadata ↓

Abstract

Cost-effectiveness analysis is increasingly recognized as an important element for health policy formation. Family physicians will be affected by these analyses because they will influence the manner and type of care that physicians offer. The principles of cost-effectiveness research are straightforward and offer primary care clinicians the opportunity to become more involved in the policies that affect their practice.

Explore related subjects

Cost-Benefit AnalysisCosts and Cost AnalysisHealth Maintenance OrganizationsHumansOutcome and Process Assessment, Health CarePrimary Health CareJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T G Ganiats. 1995. Cost-effectiveness analysis.. https://pubmed.ncbi.nlm.nih.gov/7617789/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial.

In an effort to determine the total one-year cost of liver transplantation, the underlying drivers of that cost, and any cost differences between alternative immunosuppressive regimens, an analysis was performed comparing the average one-year posttransplant charges of 322 patients participating in the "U.S. Multi-center Prospective Randomized Trial Comparing FK-506 to Cyclosporine in Liver Transplantation." Total one-year inpatient charges including all readmissions were examined. Professional fees and outpatient charges were excluded. Costs for tacrolimus drug and blood assays were assumed to be equal to those in the CsA group. For patients completing the study, the tacrolimus group had an average length of stay and average one-year cost seven days (P = .06) and $19,290 (P = .05) lower than the CsA group. The difference in rejection profiles between the two arms seems to largely account for the lower costs. The tacrolimus arm consistently had fewer patients in the more severe rejection groups. Increased incidence and severity of rejection were directly related to higher average lengths of stay and costs of transplantation (P < .001). Tacrolimus immunosuppression during the first year after liver transplantation is more cost-effective than CsA in achieving similar patient and graft survival rates. Differing incidence and severity of rejection can dramatically affect the first-year cost of liver transplantation.

Cost-Benefit Analysis↗